1. Home
  2. CMPS vs RCEL Comparison

CMPS vs RCEL Comparison

Compare CMPS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPS
  • RCEL
  • Stock Information
  • Founded
  • CMPS 2020
  • RCEL 2020
  • Country
  • CMPS United Kingdom
  • RCEL United States
  • Employees
  • CMPS N/A
  • RCEL N/A
  • Industry
  • CMPS Biotechnology: Pharmaceutical Preparations
  • RCEL Medical/Dental Instruments
  • Sector
  • CMPS Health Care
  • RCEL Health Care
  • Exchange
  • CMPS Nasdaq
  • RCEL Nasdaq
  • Market Cap
  • CMPS 280.2M
  • RCEL 308.6M
  • IPO Year
  • CMPS 2020
  • RCEL N/A
  • Fundamental
  • Price
  • CMPS $3.64
  • RCEL $8.73
  • Analyst Decision
  • CMPS Strong Buy
  • RCEL Buy
  • Analyst Count
  • CMPS 6
  • RCEL 5
  • Target Price
  • CMPS $33.60
  • RCEL $18.00
  • AVG Volume (30 Days)
  • CMPS 1.1M
  • RCEL 251.2K
  • Earning Date
  • CMPS 02-27-2025
  • RCEL 02-13-2025
  • Dividend Yield
  • CMPS N/A
  • RCEL N/A
  • EPS Growth
  • CMPS N/A
  • RCEL N/A
  • EPS
  • CMPS N/A
  • RCEL N/A
  • Revenue
  • CMPS N/A
  • RCEL $60,040,000.00
  • Revenue This Year
  • CMPS N/A
  • RCEL $36.71
  • Revenue Next Year
  • CMPS N/A
  • RCEL $54.48
  • P/E Ratio
  • CMPS N/A
  • RCEL N/A
  • Revenue Growth
  • CMPS N/A
  • RCEL 32.24
  • 52 Week Low
  • CMPS $3.17
  • RCEL $7.51
  • 52 Week High
  • CMPS $12.75
  • RCEL $18.93
  • Technical
  • Relative Strength Index (RSI)
  • CMPS 42.17
  • RCEL 31.80
  • Support Level
  • CMPS $3.29
  • RCEL $8.53
  • Resistance Level
  • CMPS $3.62
  • RCEL $9.42
  • Average True Range (ATR)
  • CMPS 0.41
  • RCEL 0.65
  • MACD
  • CMPS -0.03
  • RCEL -0.39
  • Stochastic Oscillator
  • CMPS 23.11
  • RCEL 3.89

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: